Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies

ClinicalTrials.gov ID: NCT07897669

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07897669. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CHARACTERISTICS AND OUTCOMES AMONG PATIENTS WITH DIFFERENT PREDOMINANT VARIANT HISTOLOGY TYPES OF LOCALLY ADVANCED OR METASTATIC BLADDER CARCINOMA (LA/MBC): A FLATIRON HEALTH REAL-WORLD STUDY

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer. When cancer develops, a pathologist examines a sample of the tumour under a microscope to see which cells the cancer started from. This is called the cancer's histology. Most bladder cancers begin in the cells that line the inside of the bladder and are called urothelial cancers. Less commonly, bladder cancer can develop from other cell types. The purpose of this study is to examine the types of histology that adults with advanced or metastatic bladder cancer have. The researchers will also describe the demographics (information such as age, sex and race) clinical characteristics and outcomes of those patients. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). to assess information for each participant for at least 6 months. The study will include patients' information from the database who: * Were identified to have advanced or metastatic bladder cancer. * Started their first treatment after 01 Apr 2023. * Were 18 years of age or older when they were diagnosed with advanced disease.

Study identification

NCT ID
NCT07897669
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Pfizer
Industry
Enrollment
5,122 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 4, 2026 (Actual)
Primary completion
Apr 1, 2027 (Estimated)
Completion
Apr 1, 2027 (Estimated)
Last update posted
Nov 18, 2026

2026 – 2027

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Pfizer New York New York New York 10001 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07897669, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 18, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.